proteomic-based diagnostics
Acrivon Therapeutics to Study CHK1/2 Inhibitor ACR-368, Predictive Diagnostic in Phase II Trial
The trial will enroll patients with ovarian, endometrial, and urothelial cancer, and stratify them for treatment using Acrivon's OncoSignature proteomic diagnostic.